Role of gemcitabine in cancer therapy

Future Oncology

Volumn 1, Issue 1, 2005, Pages 7-17

  Toschi, L ^a   Finocchiaro, G ^a   Bartolini, S ^b   Gioia, V ^a   Cappuzzo, F ^a  

^a BELLARIA HOSPITAL   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

Cancer; Chemotherapy; Gemcitabine

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

BLADDER TUMOR; BREAST TUMOR; DRUG INTERACTION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NEOPLASM; OVARY TUMOR; PANCREAS TUMOR; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG INTERACTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; NEOPLASMS; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 85047686771     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.1.7     Document Type: Article

References (84)

1. Crino L, Scagliotti GV, Ricci S et al.: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17(11), 3522-3530 (1999).
2. Burris HA 3rd, Moore MJ, Andersen J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403-2413 (1997).
3. Von der Maase H, Hansen SW, Roberts JT et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000).
4. Carmichael J, Possinger K, Phillip P et al.: Advanced breast cancer: A phase II trial with gemcitabine. J. Clin. Oncol. 13(11), 2731-2736 (1995).
5. Lund B, Kristjanson PEG, Hansen HH: Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine). Cancer Treat. Rev. 19, 45-55 (1994).
6. van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G: Regulation of phosphorylation of deoxycytidine and 2′,2′- difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′- triphosphate in relation to chemosensitivity for 2′,2′- difluorodeoxycytidine. Biochem. Pharmacol. 51(7), 911-918 (1996).
7. Schmid P, Akrivakis K, Flath B et al.: Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10(7), 625-631 (1999).
8. Mani S, Kugler JW, Knost JA et al.: Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest. New Drugs 16(3), 275-278 (1998-1999).
9. Tempero M, Plunkett W, Ruiz Van Haperen V et al.: Randomized phase II comparison of dose intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 21(18), 3402-3408 (2003).
10. Pavlakis N, Bell DR, Millward MJ, Levi JA: Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80(2), 286-291 (1997).
11. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J: A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85(9), 2023-2032 (1999).
12. Van Moorsel CJ, Pinedo HM, Veerman G et al.: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br. J. Cancer 80(7), 981-990 (1999).
13. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. 2(3), 521-530 (1996).
14. Van Moorsel CJ, Pinedo HM, Veerman G et al.: Combination chemotherapy studies with gemcitabine and etoposide in nonsmall cell lung and ovarian cancer cell lines. Biochem. Pharmacol. 57(4), 407-415 (1999).
15. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl Cancer Inst. 96(10), 739-749 (2004).
16. Gatzemeier U, Shepherd F, Le Chevalier T et al.: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter, extended phase II study. Eur. J. Cancer 32A(2), 243-248 (1996).
17. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in nonsmall cell lung cancer: A phase II study. J. Clin. Oncol. 12(8), 1535-1540 (1994).
18. Anderson H, Hopwood P, Stephens RJ et al.: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br. J. Cancer 83(4), 447-453 (2000).
19. Shepherd FA, Abratt RP, Anderson H et al.: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin. Oncol. 24(7), 50-55 (1997).
20. Frasci G, Lorusso V, Panza N et al.: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J. Clin. Oncol. 18(13), 2529-2536 (2000).
21. Gridelli C, Perrone F, Gallo C, et al.: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl Cancer Inst. 95(5), 362-372 (2003).
22. Cardenal F, Lopez-Cabrerizo M, Anton A et al.: Randomized phase III study of gemcitabine-cisplatin versus etoposidecisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 17(1), 12-18 (1999).
23. Sandler A, Nemunaitis J, Denham C et al.: Phase III study of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmall- cell lung cancer. J. Clin. Oncol. 18(1), 122-130 (2000).
24. Schiller JH, Harrington D, Belani CP et al.: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
25. Scagliotti GV, De Marinis F, Rinaldi M, et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20(21), 4285-4291 (2002).
26. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ: Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J. Clin. Oncol. 15(2), 744-749 (1997).
27. Rinaldi M, Crino L, Scagliotti GV et al.: A three-week schedule of gemcitabinecisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann. Oncol. 11(10), 1295-1300 (2000).
28. Ng EW, Sandler AB, Robinson L, Einhorn LH: A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study. Am. J. Clin. Oncol. 22(6), 550-553 (1999).
29. Edelman MJ: Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials. Clin. Lung Cancer. (4 Suppl. 2), S40-S44 (2003).
30. Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D: Sequential combination chemotherapy in patients with advanced non small cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92(1), 146-152 (2001).
31. Edelman MJ, Clark JI, Chansky K, et al.: Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin. Cancer Res. 10(15), 5022-5026 (2004).
32. Danson S, Middleton MR, O'Byrne KJ: Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98(3), 542-553 (2003).
33. Sederholm C: Gemcitabine versus gemcitabine/carboplatin in advanced nonsmall cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin. Oncol. 29(3 Suppl. 9):50-54 (2002).
34. Manegold C, Bergman B, Chemaissani A et al.: Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small cell lung cancer. Ann. Oncol. 8(6), 525-529 (1997).
35. Perng RP, Chen YM, Ming-Liu J et al.: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J. Clin. Oncol. 15(5), 2097-2102 (1997).
36. Vansteenkiste J, Vandebroek J, Nackaerts K et al.: Gemcitabine monotherapy vs cisplatinbased chemotherapy in symptomatic advanced NSCLC: A prospective randomized comparison of symptom control. Lung Cancer 29 (1), 48 (2001).
37. Georgoulias V, Papadakis E, Alexopoulos A et al.: Platinum-based and non-platinumbased chemotherapy in advanced nonsmall- cell lung cancer: a randomised multicentre trial. Lancet 357, 1478-1484 (2001).
38. Kosmidis P, Mylonakis N, Nicolaides C et al.: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J. Clin. Oncol. 20(17), 3578-3585 (2002).
39. Smit EF, van Meerbeeck JP, Lianes P et al.: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group- EORTC 08975. J. Clin. Oncol. 21(21), 3909-3917 (2003).
40. Krajnik G, Mohn-Staudner A, Thaler J et al.: Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer. Ann. Oncol. 11(8), 993-998 (2000).
41. Chen YM, Perng RP, Yang KY et al.: A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chest 117(6), 1583-1589 (2000).
42. Krajnik G, Wein W, Greil R et al.: Vinorelbine/gemcitabine in advanced nonsmall cell lung cancer (NSCLC): a phase I trial. Eur. J. Cancer. 34(12), 1977-1980 (1998).
43. Isokangas OP, Knuuttila A, Halme M et al.: Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann. Oncol. 10(9), 1059-1063 (1999).
44. Gridelli C, Frontini L, Perrone F et al.: Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br. J. Cancer. 83(6), 707-714 (2000).
45. Gridelli C, Cigolari S, Gallo C et al.: Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced nonsmall- cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 31(2-3), 277-284 (2001).
46. Beretta GD, Michetti G, Belometti MO et al.: Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br. J. Cancer 83(5), 573-576 (2000).
47. Herbst RS, Lilenbaum R. Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer. Semin. Oncol. 26(16), 67-70 (1999).
48. Bramhall SR, Rosemurgy A, Brown PD et al.: Marimastat as first line therapy for patients with unresectable pancreatic cancer: A randomized trial. J. Clin. Oncol. 19(15), 3447-3455 (2001).
49. Moore MJ, Hamm J, Dancey J et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21(17), 3296-3302 (2003).
50. Berlin J, Catalano P, Thomas JP et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma. J. Clin. Oncol. 20(15), 3270-3275 (2002).
51. Colucci G, Giuliani F, Gebbia V et al.: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and metastatic pancreatic carcinoma. Cancer 94(4), 902-910 (2002).
52. Bramhall SR, Schulz J, Nemunaitis J et al.: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87(2), 161-167 (2002).
53. Van Cutsem E, van de Velde H, Karasek P et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22(8), 1430-1438 (2004).
54. Rocha Lima CM, Green MR, Rotche R et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22(18), 3776-3783 (2004).
55. Possinger K, Kaufmann M, Coleman R et al.: Phase II study of gemcitabine as firstline chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10(2), 155-162 (1999).
56. Valerio MR, Cicero G, Armata MG et al.: Gemcitabine (G) in pretreated breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 20, A1953 (2001).
57. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 62(1), 2-8 (2002).
58. Spielmann M, Llombart-Cussac A, Kalla S et al.: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60(4), 303-307 (2001).
59. Brodowicz T, Moslinger R, Herscovici V et al.: Second- and third-line treatment of metastatic breast cancer with gemcitabine. Eur. J. Cancer 34, S44(5) A180 (1998).
60. Gerson R, Serrano-O A, Villalobos A et al.: Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc. Am. Soc. Clin. Oncol. 19, A572 (2000).
61. Schmid P, Akrivakis K, Flath B et al.: Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10(7), 625-631 (1999).
62. Mavroudis D, Malamos N, Alexopoulos A et al.: Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Ann. Oncol. 10(2), 211-215 (1999).
63. Rothenberg ML, Sharma A, Weiss GR et al.: Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann. Oncol. 9(7), 733-738 (1998).
64. Conte PF, Gennari A, Donati S et al.: Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res. Treat. 68(2), 171-179 (2001).
65. Cappuzzo F, Mazzoni F, Gennari A et al.: Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br. J. Cancer. 90(1), 31-35 (2004).
66. Stadler WM, Kuzel T, Roth B et al.: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. 15(11), 3394-3398 (1997).
67. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N: Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol. 15(12), 3441-3445 (1997).
68. Lorusso V, Pollera CF, Antimi M et al.: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer 34(8), 1208-1212 (1998).
69. Sternberg CN, Yagoda A, Scher HI et al.: MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol. 139(3), 461-469 (1988).
70. Moore MJ, Winquist EW, Murray N et al.: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17(9), 2876-2881 (1999).
71. Kaufman D, Raghavan D, Carducci M et al.: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18(9), 1921-1927 (2000).
72. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. 19(9), 2527-2533 (2001).
73. Fowler WC Jr, Van Le L.: Gemcitabine as a single-agent treatment for ovarian cancer. Gynecol. Oncol. 90(2 pt. 2), 21-23 (2003).
74. Du Bois A, Luck HJ, Pfisterer J et al.: Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer : a dosefinding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann. Oncol. 12,1115-1120 (2001).
75. Nagourney RA, Brewer CA, Radecki S et al.: Phase II trial of gemcitabine plus cisplatin repeating doublet therapiy in previously treated, relapsed ovarian cancer patients. Gynecol. Oncol. 88 (1), 35-39 (2003).
76. Belpomme D, Krakoski I, Beauduin M et al.: Gemcitabine combined with cisplatin as first-line treatment in patient with epithelial ovarian cancer: a phase II study. Gynecol. Oncol. 91(1), 32-38 (2003).
77. Pfisterer J, Plante M, Vergote I et al.: Gemcitabine/carboplatin (GC) vs carboplatin in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomised phase III trial of the AGO OVAR, the NCIC CTG and EORTC GCG. Proc. Am. Soc. Clin. Oncol. 23, 449 (2004).
78. Giaccone G, Herbst RS, Manegold C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 22(5):777-784 (2004).
79. Gatzemeier U, Pluzanska A, Szczesna A et al.: Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol 23, 617 (2004).
80. Kroep JR, Loves WJ, van der Wilt CL et al.: Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1(6), 371-376 (2002).
81. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64(11), 3761-3766 (2004).
82. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R: Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 95(9), 753-757 (2004).
83. Rosell R, Danenberg KD, Alberola V et al.: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10(4), 1318-1325 (2004).
84. Rosell R, Felip E, Taron M et al.: Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res. 10(12 Pt 2), 4215s-4219s (2004).